These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2325 related articles for article (PubMed ID: 31856909)

  • 1. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
    Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
    BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
    Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
    Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of immune checkpoint inhibition in early-stage NSCLC.
    Vansteenkiste J; Wauters E; Reymen B; Ackermann CJ; Peters S; De Ruysscher D
    Ann Oncol; 2019 Aug; 30(8):1244-1253. PubMed ID: 31143921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
    Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
    Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
    Cottrell TR; Thompson ED; Forde PM; Stein JE; Duffield AS; Anagnostou V; Rekhtman N; Anders RA; Cuda JD; Illei PB; Gabrielson E; Askin FB; Niknafs N; Smith KN; Velez MJ; Sauter JL; Isbell JM; Jones DR; Battafarano RJ; Yang SC; Danilova L; Wolchok JD; Topalian SL; Velculescu VE; Pardoll DM; Brahmer JR; Hellmann MD; Chaft JE; Cimino-Mathews A; Taube JM
    Ann Oncol; 2018 Aug; 29(8):1853-1860. PubMed ID: 29982279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
    BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design.
    Garrido P; Pujol JL; Kim ES; Lee JM; Tsuboi M; Gómez-Rueda A; Benito A; Moreno N; Gorospe L; Dong T; Blin C; Rodrik-Outmezguine V; Passos VQ; Mok TS
    Future Oncol; 2021 Apr; 17(12):1459-1472. PubMed ID: 33648347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.
    Jafarnejad M; Gong C; Gabrielson E; Bartelink IH; Vicini P; Wang B; Narwal R; Roskos L; Popel AS
    AAPS J; 2019 Jun; 21(5):79. PubMed ID: 31236847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative Nivolumab in Resectable Lung Cancer.
    Cascone T; Awad MM; Spicer JD; He J; Lu S; Sepesi B; Tanaka F; Taube JM; Cornelissen R; Havel L; Karaseva N; Kuzdzal J; Petruzelka LB; Wu L; Pujol JL; Ito H; Ciuleanu TE; de Oliveira Muniz Koch L; Janssens A; Alexandru A; Bohnet S; Moiseyenko FV; Gao Y; Watanabe Y; Coronado Erdmann C; Sathyanarayana P; Meadows-Shropshire S; Blum SI; Provencio Pulla M;
    N Engl J Med; 2024 May; 390(19):1756-1769. PubMed ID: 38749033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
    Bott MJ; Yang SC; Park BJ; Adusumilli PS; Rusch VW; Isbell JM; Downey RJ; Brahmer JR; Battafarano R; Bush E; Chaft J; Forde PM; Jones DR; Broderick SR
    J Thorac Cardiovasc Surg; 2019 Jul; 158(1):269-276. PubMed ID: 30718052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
    Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
    Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Schvartsman G; Peng SA; Bis G; Lee JJ; Benveniste MFK; Zhang J; Roarty EB; Lacerda L; Swisher S; Heymach JV; Fossella FV; William WN
    Lung Cancer; 2017 Oct; 112():90-95. PubMed ID: 29191606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases.
    Angela Y; Haferkamp S; Weishaupt C; Ugurel S; Becker JC; Oberndörfer F; Alar V; Satzger I; Gutzmer R
    Cancer Immunol Immunother; 2019 Jul; 68(7):1187-1194. PubMed ID: 31187176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
    Reuss JE; Anagnostou V; Cottrell TR; Smith KN; Verde F; Zahurak M; Lanis M; Murray JC; Chan HY; McCarthy C; Wang D; White JR; Yang S; Battafarano R; Broderick S; Bush E; Brock M; Ha J; Jones D; Merghoub T; Taube J; Velculescu VE; Rosner G; Illei P; Pardoll DM; Topalian S; Naidoo J; Levy B; Hellmann M; Brahmer JR; Chaft JE; Forde PM
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
    Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
    Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
    Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
    Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 117.